Atlas Trials

The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor

Clinical trial NCT03505164 · COMPLETED

Trial details

NCT number
NCT03505164
Sponsor
Rush University Medical Center
Status
COMPLETED
Study type
OBSERVATIONAL
Doxorubicin Adverse ReactionCardiomyopathies, SecondaryBreast Cancer
Start date
2017-01-17
Primary completion
2020-07-06
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.